GlassScriptPhysician profile
Kanwal M Khan
NPI 1659537454
$9,752.77
in general payments reported to CMS, 2019-2025
46 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $1,240 · 2021: $1,058 · 2022: $1,416 · 2023: $1,873 · 2024: $1,391 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,864.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,108.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,033.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $970.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $846.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $775.35 | 2019-2025 | |
| Amgen INC. | $773.60 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $401.74 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $330.45 | 2019-2025 | |
| Abbott Laboratories | $272.09 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.85 | 2019-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $245.46 | 2022-2025 | |
| Exact Sciences Corporation | $238.44 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.75 | 2020-2025 | Jardiance |
| Esperion Therapeutics, INC. | $197.03 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $146.65 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanwal Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.